President Donald Trump said he is weighing an executive order that would move marijuana to Schedule III, a change that could reshape research, taxation, and policing nationwide. The comment came as his administration considers how to respond to growing public support for reform and the needs of medical researchers. The signal sets up a major policy test for federal drug law and for an industry operating under a patchwork of state rules.
“I am considering an executive order to reclassify marijuana as a Schedule III drug,” President Donald Trump said, citing research benefits and public demand for policy reform.
What Schedule III Would Mean
Marijuana is currently listed as Schedule I under the Controlled Substances Act, alongside heroin, with a legal finding of high abuse potential and no accepted medical use. Schedule III includes drugs like ketamine and certain anabolic steroids. These drugs have accepted medical use and lower abuse risk than Schedules I and II.
Rescheduling would not legalize recreational use under federal law. It would, however, open doors to federally funded studies, allow doctors and universities to handle cannabis under less restrictive rules, and remove a major tax penalty known as 280E. That tax rule now bars state-licensed cannabis businesses from deducting many normal expenses, inflating their effective tax rates.
Public Support And State Trends
Voters in many states have already moved ahead. Medical cannabis is legal in most states, and more than 20 have legalized adult-use sales. Polling over the past several years shows consistent majority support for reform across party lines.
Advocates argue that federal change would align policy with on-the-ground reality. “Patients and researchers should not face the same hurdles as traffickers,” one policy analyst said in a recent discussion, pointing to limited access for clinical trials and barriers to studying dosage and safety.
Can An Executive Order Do It?
Legal experts say a president cannot unilaterally rewrite the drug schedules. The Controlled Substances Act places that authority with the Drug Enforcement Administration, following medical and scientific evaluation by the Department of Health and Human Services. An executive order could direct those agencies to act quickly, set deadlines, and prioritize rescheduling, but rulemaking would still be required.
That process includes public notice, comment, and a final rule that may face court challenges. Industry groups, patient advocates, and opponents are likely to weigh in. Timelines could stretch months.
History And Momentum
Pressure for change has built for years. Under the prior administration, HHS recommended moving marijuana to Schedule III after a scientific review. DEA later proposed the same shift and gathered public comments. No final rule has cleared every step of the process.
Trump’s signal adds fresh political weight. It also raises questions about how his Justice Department would handle prosecutions and guidance to U.S. attorneys while rulemaking proceeds.
What Could Change Quickly
- Research: Easier access for universities and hospitals, with standard supply chains for studies.
- Taxation: Relief from 280E, potentially improving margins for licensed operators.
- Banking: While rescheduling does not change anti-money-laundering laws, it may ease risk perceptions for lenders.
- Criminal Justice: Federal penalties would adjust, but state laws would still control most arrests and prosecutions.
Supporters And Skeptics
Supporters say rescheduling would “bring science into the lab, not the courtroom,” as one researcher put it, noting that current rules limit dosing research and product safety testing. They also point to steep tax burdens that push legal operators to raise prices while illicit sellers face no such costs.
Critics warn that moving to Schedule III without full safety data could send mixed signals. Some law enforcement leaders argue that impaired driving and youth access remain concerns. Others contend that rescheduling stops short of addressing conflicts between federal and state laws that complicate banking, insurance, and interstate commerce.
The Road Ahead
If the White House issues an order, the next steps would likely come from HHS and DEA in the form of an accelerated rulemaking timeline. Courts could be asked to review the agencies’ scientific basis and procedures. Congress could also intervene with legislation that sets standards for research, banking, and taxation.
The proposal marks a turning point for federal cannabis policy. If carried out, Schedule III status would not settle every issue, but it would remove key bottlenecks. Researchers could run larger trials. Businesses could claim normal deductions. Regulators could set clearer rules for safety and labeling.
For now, the central questions are speed and scope. How fast can agencies move, and how broad will the final rule be? The answers will shape medical research, state markets, and federal enforcement for years to come.
